James brings extensive experience across biotechnology, clinical diagnostics, and laboratory operations, with a strong focus on the translation of novel tests into high-throughput clinical services.

Prior to joining the Future Medicines Institute, James held senior roles at Randox Laboratories, most recently as Head of Genomics Services and Strategy, where he led global operations in clinical and microbial sequencing, molecular test development, and service delivery for public health and private sector partners. He played a central role in the implementation of novel tests with regulatory compliance under ISO15189, IVDR, CE-IVD, and UKCA frameworks.

James also held operational leadership positions during the COVID-19 pandemic, overseeing one of Europe’s largest SARS-CoV-2 testing and sequencing laboratories with capacities exceeding 160,000 samples per day. His work encompassed end-to-end project delivery including laboratory design, ISO17025/15189 compliance, and the deployment of advanced NGS technologies.

Earlier in his career, James worked as an R&D Scientist, where he was involved in the development and production of recombinant antibody fragments for use in diagnostic and therapeutic applications. His expertise included antibody characterisation, affinity purification, and the use of bacterial, phage and mammalian systems.

At FMI, James supports the strategic and operational delivery of multidisciplinary research programs, working to accelerate the translation of innovative science into practical healthcare solutions.